Drug intelligence / Profile preview

AL003

Development stage: Discontinued
Lead developer: Alector
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AL003 is a monoclonal antibody developed to target sialic acid binding Ig-like lectin 3 (SIGLEC 3), also known as myeloid cell surface antigen CD33. SIGLEC 3/CD33 is an inhibitory receptor expressed primarily on microglia, the immune cells of the central nervous system. By blocking SIGLEC 3/CD33, AL003 aims to increase microglial activity and enhance the brain’s immune response against pathologies associated with Alzheimer’s disease. The drug was co-developed by Alector and AbbVie for the treatment of Alzheimer’s disease but was discontinued after Phase 1 clinical trials[4][5][6][7][9].

Other names: anti-CD33 PGLALA antibodyanti-CD-33 PGLALA antibodyanti-CD 33 PGLALA antibodyAlector CD33 antibody

Targets

CD33 (Myeloid cell surface antigen CD33)

Beyond the preview

Go deeper on AL003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AL003.

Explore the full profile